Paper36980210
Evaluation and Application of Drug Resistance by Biomarkers in the Clinical Treatment of Liver Cancer.
Huang PS and 7 others. Cells, 2023. Cited by 20 papers, by iCite.
Cite this record
ConductScience Library. Evaluation and Application of Drug Resistance by Biomarkers in the Clinical Treatment of Liver Cancer. Papers, record 36980210. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36980210
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Evaluation and Application of Drug Resistance by Biomarkers in the Clinical Treatment of Liver Cancer.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| alpha-Fetoproteins | Major topic |
| Liver Neoplasms | Major topic |
| Humans | |
| Early Detection of Cancer | |
| Biomarkers | |
| Drug Resistance |
Source PubMed
References195
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35223830 | The Roles of EphB2 in Cancer. | Front Cell Dev Biol | 2022 | https://conductscience.org/library/papers/35223830 | PubMed |
| 2 | 34282052 | Aberrant expression of WDR4 affects the clinical significance of cancer immunity in pan-cancer. | Aging (Albany NY) | 2021 | https://conductscience.org/library/papers/34282052 | PubMed |
| 3 | 34414118 | Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study. | Liver Cancer | 2021 | https://conductscience.org/library/papers/34414118 | PubMed |
| 4 | 32035242 | Role of miR-21 as an authentic oncogene in mediating drug resistance in breast cancer. | Gene | 2020 | https://conductscience.org/library/papers/32035242 | PubMed |
| 5 | 18650514 | Sorafenib in advanced hepatocellular carcinoma. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18650514 | PubMed |
| 6 | 32373951 | LncRNA NEAT1 regulates proliferation, apoptosis and invasion of liver cancer. | Eur Rev Med Pharmacol Sci | 2020 | https://conductscience.org/library/papers/32373951 | PubMed |
| 7 | 32782275 | Targeted therapy for hepatocellular carcinoma. | Signal Transduct Target Ther | 2020 | https://conductscience.org/library/papers/32782275 | PubMed |
| 8 | 33456577 | Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2. | Theranostics | 2021 | https://conductscience.org/library/papers/33456577 | PubMed |
| 9 | 25923690 | Systematic Review and Meta-Analysis of the Relationship between EPHX1 Polymorphisms and the Risk of Head and Neck Cancer. | PLoS One | 2015 | https://conductscience.org/library/papers/25923690 | PubMed |
| 10 | 33209421 | The impacts of ubiquilin 1 (UBQLN1) knockdown on cells viability, proliferation, and apoptosis are mediated by p53 in A549 lung cancer cells. | J Thorac Dis | 2020 | https://conductscience.org/library/papers/33209421 | PubMed |
| 11 | 34658879 | YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/34658879 | PubMed |
| 12 | 34914889 | Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. | Lancet Oncol | 2022 | https://conductscience.org/library/papers/34914889 | PubMed |
| 13 | 31024205 | Hepatocellular Carcinoma: Etiology and Current and Future Drugs. | J Clin Exp Hepatol | 2019 | https://conductscience.org/library/papers/31024205 | PubMed |
| 14 | 32506767 | MiR-145 in cancer therapy resistance and sensitivity: A comprehensive review. | Cancer Sci | 2020 | https://conductscience.org/library/papers/32506767 | PubMed |
| 15 | 31038847 | Genetic variants in a long noncoding RNA related to Sunitinib Resistance predict risk and survival of patients with renal cell carcinoma. | Cancer Med | 2019 | https://conductscience.org/library/papers/31038847 | PubMed |
| 16 | 16357600 | EPHX1 polymorphisms and the risk of lung cancer: a HuGE review. | Epidemiology | 2006 | https://conductscience.org/library/papers/16357600 | PubMed |
| 17 | 33823894 | Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling. | J Exp Clin Cancer Res | 2021 | https://conductscience.org/library/papers/33823894 | PubMed |
| 18 | 30391438 | lncARSR promotes liver cancer stem cells expansion via STAT3 pathway. | Gene | 2019 | https://conductscience.org/library/papers/30391438 | PubMed |
| 19 | 32019286 | Activation of Tyrosine Metabolism in CD13+ Cancer Stem Cells Drives Relapse in Hepatocellular Carcinoma. | Cancer Res Treat | 2020 | https://conductscience.org/library/papers/32019286 | PubMed |
| 20 | 35184646 | microRNA-378a-3p regulates the progression of hepatocellular carcinoma by regulating PD-L1 and STAT3. | Bioengineered | 2022 | https://conductscience.org/library/papers/35184646 | PubMed |
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42294982 | Downregulation of GMPS inhibited the proliferation of hepatocellular cancer cells via the regulation of STAT3/c-Myc pathway. | Eur J Histochem | 2026 | https://conductscience.org/library/papers/42294982 | PubMed |
| 42210102 | CCNA2, MAD2L1, AURKA, and PTTG1 promote proliferation and migration in hepatocellular carcinoma. | BMC Gastroenterol | 2026 | https://conductscience.org/library/papers/42210102 | PubMed |
| 42048041 | Squalene attenuates doxorubicin resistance in hepatocellular carcinoma by targeting SIRT6 to inhibit ERK1 deacetylation. | Mol Cell Biochem | 2026 | https://conductscience.org/library/papers/42048041 | PubMed |
| 42014849 | γ-terpinene inhibits the progression of hepatocellular carcinoma by regulating the PTEN/PI3K/Akt signaling pathway mediated glycolysis. | Sci Rep | 2026 | https://conductscience.org/library/papers/42014849 | PubMed |
| 41972163 | CD24 as an innate immune checkpoint in solid tumors: biology, biomarker stratification, and therapeutic translation. | Front Immunol | 2026 | https://conductscience.org/library/papers/41972163 | PubMed |
| 41642374 | Combination of sodium pentaborate pentahydrate, curcumin and piperine treatment induces ferroptosis in hepatocellular carcinoma cells by regulating iron homeostasis and ROS activity in vitro. | Med Oncol | 2026 | https://conductscience.org/library/papers/41642374 | PubMed |
| 40347395 | The effect of continuous infusion chemotherapy through femoral artery catheterization on GP73, AFP-L3, and safety efficacy in liver cancer patients. | Clin Exp Med | 2025 | https://conductscience.org/library/papers/40347395 | PubMed |
| 40291897 | Novel multimodal analgesic regimen for perioperative pain management after hepatic artery infusion chemotherapy in patients with advanced hepatocellular carcinoma. | World J Gastrointest Surg | 2025 | https://conductscience.org/library/papers/40291897 | PubMed |
| 39822558 | Exploring potential key genes and pathways associatedwith hepatocellular carcinoma prognosis through bioinformatics analysis, followed by experimental validation. | Am J Transl Res | 2024 | https://conductscience.org/library/papers/39822558 | PubMed |
| 39816559 | Mitochondrial cholesterol metabolism related gene model predicts prognosis and treatment response in hepatocellular carcinoma. | Transl Cancer Res | 2024 | https://conductscience.org/library/papers/39816559 | PubMed |
| 39664575 | NR4A3 inhibits the tumor progression of hepatocellular carcinoma by inducing cell cycle G0/G1 phase arrest and upregulation of CDKN2AIP expression. | Int J Biol Sci | 2024 | https://conductscience.org/library/papers/39664575 | PubMed |
| 39105941 | Cytoprotective effect of garlic alone versus co-administration of garlic and resveratrol in adriamycin-induced lung toxicity in albino rat: light microscopic, ultrastructural and immunohistochemical study. | J Mol Histol | 2024 | https://conductscience.org/library/papers/39105941 | PubMed |
| 38997696 | Intricate effects of post-translational modifications in liver cancer: mechanisms to clinical applications. | J Transl Med | 2024 | https://conductscience.org/library/papers/38997696 | PubMed |
| 38737681 | Potential role of lncRNA LOXL1-AS1 in human cancer development: a narrative review. | Transl Cancer Res | 2024 | https://conductscience.org/library/papers/38737681 | PubMed |
| 38650929 | Ferroptosis in liver cancer: a key role of post-translational modifications. | Front Immunol | 2024 | https://conductscience.org/library/papers/38650929 | PubMed |
Genes128
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36980210
GET https://conductscience.org/api/papers/v1/36980210/references?page=2